1. Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

   • L. G. Estévez
   • E. García
   • M. Hidalgo

   Review Article 28 October 2015 Pages: 541 - 549

   

2. Molecular biology of testicular germ cell tumors

   • R. Gonzalez-Exposito
   • M. Merino
   • C. Aguayo

   Review Article 19 October 2015 Pages: 550 - 556

   

3. Management of infection and febrile neutropenia in patients with solid cancer

   • J. A. Virizuela
   • J. Carratalà
   • J. J. Cruz

   Clinical Guides in Oncology 17 November 2015 Pages: 557 - 570

   

4. Concurrent chemo-radiotherapy in elderly patients: tolerance and compliance in a series of 137 patients

   • M. Di Genesio Pagliuca
   • C. Perotti
   • M. Krengli

   Research Article 14 September 2015 Pages: 571 - 575

5. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials

   • T. T. Zhang
   • R. M. Wang
   • G. B. Chen

   Research Article 02 November 2015 Pages: 576 - 581

   

6. The position and current status of radiation therapy after primary systemic therapy in breast cancer: a national survey-based expert consensus statement

   • M. Arenas
   • Á. Montero
   • M. Algara

   Research Article 14 September 2015 Pages: 582 - 591

7. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma

   • J. Jia
   • Y. Cui
   • X. Zhang

   Research Article 12 October 2015 Pages: 592 - 598

   

8. Prognostic value of tropomyosin-related kinases A, B, and C in gastric cancer

   • A. Kamiya
   • M. Inokuchi
   • K. Kojima

   Research Article 12 October 2015 Pages: 599 - 607

   

9. Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy

   • D. Aydin
   • A. Bilici
   • M. Aliustaoglu

   Research Article 12 October 2015 Pages: 608 - 616

   

10. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

    • M. Ozcelik
    • H. Odabas
    • M. Gumus

    Research Article 12 October 2015 Pages: 617 - 624

    

11. Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?

    • H. J. Park
    • K. Kim
    • S. W. Ha

    Research Article 12 October 2015 Pages: 625 - 631

    

12. Visceral obesity stimulates anaphase bridge formation and spindle assembly checkpoint dysregulation in radioresistant oesophageal adenocarcinoma

    • A. M. Mongan
    • N. Lynam-Lennon
    • J. O’Sullivan

    Research Article 16 October 2015 Pages: 632 - 640

    

13. Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis

    • R.-H. Tian
    • Y.-G. Zhang
    • H.-L. Ji

    Research Article 12 October 2015 Pages: 641 - 649

    

14. Erratum to: Autologous tumor lysate/Bacillus Calmette–Guérin immunotherapy as an adjuvant to conventional breast cancer therapy

    • J. Convit
    • H. Montesinos
    • L. E. Palacios

    Erratum 19 April 2016 Pages: 650 - 650

15. Erratum to: Visceral obesity stimulates anaphase bridge formation and spindle assembly checkpoint dysregulation in radioresistant oesophageal adenocarcinoma

    • A. M. Mongan
    • N. Lynam-Lennon
    • J. O’Sullivan

    Erratum 20 November 2015 Pages: 651 - 651